AVEO Pharma Sets IPO Terms

AVEO Pharmaceuticals Inc., a Cambridge, Mass.-based oncology drug company, has set its IPO terms to seven million common shares being offered at between $13 and $15 per share. It would have an initial market cap of approximately $415 million, were it to price at the high end of its range.

The company plans to trade on the Nasdaq under ticker symbol AVEO, with J.P. Morgan and Morgan Stanley serving as co-lead underwriters.

AVEO has raised around $151 million in VC funding, from firms like Biogen Idec (14% pre-IPO stake), MPM Capital (10.7%), Highland Capital Partners (9.9%), Venrock (8%), Prospect Venture Partners (7.8%), Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group, Flagship Ventures, Oxford Bioscience Partners, Greylock Partners, Lotus Biosciences, GE Capital and Vatera Holdings. www.aveopharma.com

Related Posts

1 Comment

  • [...] Aveo Pharmaceuticals, a drug company focused on cancer therapeutics, set the estimated price range for its initial public offering, saying it will offer seven million common shares at between $13 and $15 per share, peHUBreported. [...]

Leave a Reply

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget